Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)

DRUG3 trials

Sponsors

Bayer

Conditions

CardiomyopathiesHeart DiseasesMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Phase 2

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

CompletedNCT00185250

BayerCardiomyopathies, Heart Diseases

Start: 2002-12-31End: 2005-11-30Updated: 2008-12-19

Phase 3

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

CompletedNCT00099502

BayerMultiple Sclerosis, Relapsing-Remitting

Start: 2003-11-30End: 2007-08-31Updated: 2008-12-19

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

WithdrawnNCT00313976

BayerMultiple Sclerosis

Updated: 2015-03-10

Related Papers

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

2009-09-02273 citations